Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

被引:0
|
作者
Yu, Jiahui [1 ]
Yan, Duan [1 ]
Wei, Song [1 ]
Yang, Linfeng [1 ]
Yi, Pengsheng [1 ]
机构
[1] North Sichuan Med Coll, Affiliated Hosp, Dept Hepatobiliary Pancreas 2, 1 Maoyuan South Rd, Nanchong 637000, Sichuan, Peoples R China
关键词
transcatheter arterial chemoembolization; tyrosine kinase inhibitors; camrelizumab; hepatocellular carcinoma; meta-analysis; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; MULTICENTER; APATINIB; THERAPY; ANTIBODIES; LENVATINIB; TRIALS;
D O I
10.3892/ol.2024.14534
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transcatheter arterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and camrelizumab (collectively: T-T-C) is a novel treatment strategy for unresectable hepatocellular carcinoma (HCC). The present systematic review and meta-analysis aimed to evaluate the efficacy and safety of T-T-C compared with TACE combined with TKIs only (T-T) in the treatment of patients with unresectable HCC. A systematic literature search was conducted on T-T and T-T-C using PubMed, Embase and the Cochrane Library. Data regarding the clinical outcome, including overall survival (OS), progression-free survival (PFS), tumor response and adverse events (AEs), were independently extracted and analyzed by two researchers using standardized protocols. In total, 7 cohort studies, including 1,798 patients (T-T-C, 838; T-T, 960), were included in the meta-analysis. The results of the present study demonstrated that the T-T-C group had significantly prolonged OS [hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.29-0.50; I2=61.5%; P=0.016)] and PFS (HR, 0.37; 95% CI, 0.30-0.46; I2=44.5%; P=0.109), and showed significantly higher objective response rates [risk ratio (RR), 0.82; 95% CI, 0.69-0.96; I2=25.1%; P=0.237)] and slightly higher disease control rates without a significant difference (RR, 0.96; 95% CI, 0.89-1.03; I2=0.0%; P=0.969). In addition, grade 3/4 AEs were more common in the T-T group, including hypertension (RR, 1.15; 95% CI, 0.85-1.56), vomiting or nausea (RR, 0.88; 95% CI, 0.44-1.76) and pain (RR, 0.74; 95% CI, 0.45-1.21); however, these results were not statistically significant. In conclusion, compared with T-T combination therapy, T-T-C demonstrated a notable advantage in terms of OS, PFS, ORR and DCR in patients with unresectable HCC. For manageable AEs, although the results were not statistically significant, the incidence of AEs in the T-T group was higher than that in the T-T-C group in terms of event probability.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Han Li
    Zhenying Wu
    Jiali Chen
    Ke Su
    Lu Guo
    Ke Xu
    Tao Gu
    Yi Jiang
    Pan Wang
    Hao Zeng
    Hao Chi
    Kun He
    Yunwei Han
    Clinical and Experimental Medicine, 2023, 23 : 1537 - 1549
  • [32] External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Li, Han
    Wu, Zhenying
    Chen, Jiali
    Su, Ke
    Guo, Lu
    Xu, Ke
    Gu, Tao
    Jiang, Yi
    Wang, Pan
    Zeng, Hao
    Chi, Hao
    He, Kun
    Han, Yunwei
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (05) : 1537 - 1549
  • [33] Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Yang, Man
    Yuan, Jin-Qiu
    Bai, Ming
    Han, Guo-Hong
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (10) : 6575 - 6582
  • [34] Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Junning Liu
    Linfeng Yang
    Song Wei
    Jijiang Li
    Pengsheng Yi
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16191 - 16201
  • [35] Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Liu, Junning
    Yang, Linfeng
    Wei, Song
    Li, Jijiang
    Yi, Pengsheng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (17) : 16191 - 16201
  • [36] Camrelizumab combined with transcatheter arterial chemoembolization for intermediate or advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Liu, Li
    He, Wenyu
    Liu, Jiaoping
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (09)
  • [37] Efficacy and safety of immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC): A systematic review and meta-analysis of randomized clinical trials (RCTs).
    Jacome, Alexandre A.
    Guimaraes De Castro, Ana Carolina
    Solar Vasconcelos, Joao Paulo
    Cruz Rangel Silva, Maria Helena
    Oliveira Lessa, Marco Antonio
    de Moraes, Eduardo Dias
    Andrade, Aline Chaves
    Figueiredo Ferreira, Barbara Sodre
    Lima, Frederico M. T.
    Bulcao, Marcela Lima
    Ferreira, Artur Rodrigues
    Fogacci De Farias, Joao Paulo
    Prolla, Gabriel
    Garicochea, Bernardo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] The efficacy of tyrosine kinase inhibitors combined with chemotherapy for recurrent ovarian cancer: a systematic review and network meta-analysis
    Chen, Haitang
    Li, Renliang
    Wu, Jiaohong
    MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH, 2024, 36 (02): : 81 - 95
  • [39] Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis
    Fachi, Mariana M.
    Tonin, Fernanda S.
    Leonart, Leticia P.
    Aguiar, Karina S.
    Lenzi, Luana
    Figueiredo, Bonald C.
    Fernandez-Llimos, Fernando
    Pontarolo, Roberto
    EUROPEAN JOURNAL OF CANCER, 2018, 104 : 9 - 20
  • [40] Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
    Feng, Jingwen
    Zhao, Yi
    Zhai, Lin
    Zhou, Jingxu
    MEDICINE, 2024, 103 (18) : E37997